Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma.

ABSTRACT:

Background

Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors. We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor) for patients with advanced mucosal melanoma (MM), and explore-related biomarkers.

Methods

We conducted a single-center, open-label, single-arm, phase II study. Patients with unresectable or recurrent/metastatic MM received camrelizumab and apatinib. The primary endpoint was the confirmed objective response rate (ORR).

Results

Between April 2019 and June 2022, 32 patients were enrolled, with 50.0%

SUBMITTER: Zhao L 

PROVIDER: S-EPMC11328654 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature